Research: fingolimod (Gilenya) me toos


CS-0777 is a selective sphingosine 1-phosphate receptor-1 modulator under investigation for treatment of MS. The investigators conducted an open-label, pilot study in 25 MSers to assess the safety, pharmacokinetics, pharmacodynamics and exploratory efficacy of oral CS-0777 (0.1, 0.3 and 0.6mg), administered once weekly or every other week for 12weeks. CS-0777 resulted in a pronounced, dose-dependent decrease in lymphocytes and CD4 T cell subsets, which returned to baseline within 4 weeks after the last dose. Overall, CS-0777 was safe and well-tolerated. These results require confirmation in a double-blind, placebo-controlled and adequately powered phase 2 study in MS.

The S1P1 receptor

Pharmaceutical companies are like lemmings or should I say sharks, so once one gets a smell of blood or in this case money they all follow in the path of those that go before them. Maybe they  can form a cartel to fix price as there seldom seems to be a price war. CS-0777 is another version of Fingolimod (Gilenya). There are a number of others. Will this have the same side-effect profile as Fingolimod (Gilenya)? Yes, if the mechanism of action and the side effects are mediated via the sphingosine 1-phosphate receptor-1. 

About the author


1 comment

  • "Maybe they can form a cartel to fix price as there seldom seems to be a price war."

    One of the (many) areas where the theories of Adam Smith in "The Wealth of Nations" do not apply. So much for market forces! The concept of charging what the market will stand applies, as always.
    How much does it take to manufacture these S-1-P-1 antagonists? Not much, I'll bet.
    Just remember, for the average pharma company, the marketing budget is at least twice as much as the research budget.
    Now that's off my chest, I feel better!
    Hope to see as many of you as possible at MS Life this weekend!

By MouseDoctor



Recent Posts

Recent Comments